Theraclion (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, announce that the first patients were treated in the U.S. pivotal clinical trial to evaluate the safety and efficacy of Echopulse® echotherapy as a non-invasive treatment of breast fibroadenomas (BFAs).